Key result
Real-world sacubitril/valsartan prescribing adheres to NICE guidelines, with ~99% of patients meeting NYHA criteria.
Why the study?
Sacubitril/valsartan reduces mortality and hospitalisation in heart failure, but real-life prescribing data in accordance with national guidelines needed exploration across hospitals.
Observational (n=118)
Yes
Real-world prescribing of sacubitril/valsartan in the UK adheres well to NICE guidelines regarding patient eligibility, but overall uptake remains lower than expected.
Answers are grounded in this paper and cite their sources.
High real-world adherence supports appropriate sacubitril/valsartan initiation; leaves open barriers to greater HF uptake.
Background: Sacubitril/valsartan is a combination drug therapy for heart failure (HF) patients that has been shown to reduce mortality and hospitalisation. Aims: To explore clinically relevant real-life patient data regarding prescribing of sacubitril/valsartan for HF patients in three hospitals, in accordance with national guidelines. Methods: A retrospective multicentre study in three large UK hospital Trusts based in the West Midlands. Findings: A total of 118 symptomatic chronic HF patients with reduced ejection fraction were included in the study. A high proportion of prescribers adhered to NICE guidelines for treatment with sacubitril/valsartan; 99% of patients had a New York Heart Association functional class of at least II; 82% had a left ventricle ejection fraction of under 35%; 100% received an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker before commencing sacubitril/valsartan. The mean age of men and women at the three hospitals was 65 and 59 years, respectively. The proportion of men prescribed sacubitril/valsartan was greater than women: 80% compared to 20%, respectively. The majority of patients on the therapy were white British (65%). Total prescribing of sacubitril/valsartan at the three hospitals was 295 patients, lower than expected. Conclusion: The prescribing of sacubitril/valsartan at the Trusts generally adhered to NICE guidance; however, the prescribing rate was lower than expected compared with the NICE resource tool. Further investigations into the safety and scope of application of sacubitril/valsartan are required to match the prescribing of sacubitril/valsartan with eligible patients who could benefit from the medication.
No takes yet. Share an insight, caveat, or question.
Jalal et al. (2019) conducted an observational in symptomatic chronic heart failure with reduced ejection fraction (n=118). Sacubitril/valsartan was evaluated on Adherence to NICE guidelines for treatment with sacubitril/valsartan. Prescribing of sacubitril/valsartan for heart failure generally adhered to NICE guidelines, with 99% of patients having functional class ≥II and 100% receiving prior ACEi/ARB therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: